Singapore-based life sciences ecosystem builder Esco Group is investing $15 million into a new manufacturing and innovation complex in China, with the aim of serving the rapidly growing Chinese market and address unmet needs for Chinese patients.

The 20,00-square-meter manufacturing and innovation complex is scheduled to be completed by end of 2019.

The Esco Jiangsu Innovation Centre, located in Taicang, Suzhou, Jiangsu, just 50 kilometers away from central Shanghai, will be a platform for acceleration and commercialization of life sciences, medical devices, reproductive medicine, and precision medicine technologies.

The company will continue to invest in local R&D, collaborate with academic institutions, and establish in-licensing or joint ventures with global startups to commercialize its technologies in China.